RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-Centre Prospective Placebo Controlled Cohort Dose Escalation Study (RE-DEEM).

Trial Profile

RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-Centre Prospective Placebo Controlled Cohort Dose Escalation Study (RE-DEEM).

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2014

At a glance

  • Drugs Dabigatran etexilate (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Embolism and thrombosis
  • Focus Adverse reactions; Registrational
  • Acronyms RE-DEEM; RE-VOLUTION
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Mar 2012 Planned number of patients changed from 1878 to 2220 as reported by European Clinical Trials Database.
    • 07 May 2011 Results published in the European Heart Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top